PeptideDB

IMS2186

CAS: 1031206-36-6 F: C18H16O4 W: 296.32

IMS2186 is an antichoroidal neovascularization (CNV) reagent. IMS2186 can arrest cancer cell cycle in G2/M phase, thus e
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

Bioactivity IMS2186 is an antichoroidal neovascularization (CNV) reagent. IMS2186 can arrest cancer cell cycle in G2/M phase, thus exerting anti-proliferation and anti-angiogenesis effects. IMS2186 has no intraocular toxicity and reduces the amount of eye leakage and diseased cells[1].
Invitro IMS2186 (0.3-10 μM; 22 h) 抑制剂人成纤维细胞、人癌症细胞增殖,IC50 分别为 1.0-3.0 μM,0.3-3.0 μM[1]。IMS2186 (0-10 μM; 22 h) 在 10 ng/mL VEGF 刺激下,抑制内皮管形成,IC50 为 0.1-0.3 μM[1]。IMS2186 (0.1-10 μM; 24 h) 抑制巨噬细胞中促炎细胞因子 PGE2/TNF-a 的产生,IC50 为 0.3-1 μM[1]。IMS2186 (0.1-10 μM; 1.5 h) 还抑制巨噬细胞迁移,IC50 为 1 μM[1]。 Cell Cycle Analysis[1] Cell Line:
In Vivo IMS2186 (2.5 mg in 0.5 mL; 玻璃体注射; 单次剂量) 施用于兔子眼睛后,未出现眼毒性[1]。IMS2186 (100 μg/眼,即 50 μg/μL 溶液用量 2.0 μL; 单次剂量) 对激光诱导脉络膜新生血管 (CNV) 的大鼠模型表现出抗增殖效力[1]。 Animal Model:
Name IMS2186
CAS 1031206-36-6
Formula C18H16O4
Molar Mass 296.32
Appearance Solid
Transport Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
Reference [1]. Falkenstein IA, et al. Toxicity and intraocular properties of a novel long-acting anti-proliferative and anti-angiogenic compound IMS2186. Curr Eye Res. 2008 Jul;33(7):599-609.